Hydra Biosciences develops novel drugs to treat pain, inflammation, anxiety and other diseases using its expertise in novel ion channels.

The company’s proprietary high throughput screening platforms and integrated pharmacology and chemistry infrastructure enable it to identify and develop drug candidates that address significant unmet medical needs. Hydra’s most advanced product is in phase 1 clinical trials, and the company has a strategic relationship with Cubist Pharmaceuticals.